Figure 2
From: MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Kaplan-Meier cumulative survival (months) in glioblastoma patients. According to promoter methylation status of (A) MGMT gene (log-rank test, χ 2=7.997, df = 1, P = 0.005), (B) GATA6 gene (log-rank test, χ 2 = 1.582, df = 1, P = 0.208), (C) CD81 gene (log-rank test, χ 2 = 0.719, df = 1, P = 0.395), (D) DR4 gene (log-rank test, χ 2 = 1.800, df = 1, P = 0.180), and (E) CASP8 gene (log-rank test, χ 2 = 4.214 df = 1, P = 0.040).